Tolterodine (Detrol)

Trade name Detrol

Has a bioavailability of 77%, and protein binding of approximately 96.3%.

An antimuscarinic drug that is used for symptomatic treatment of urinary incontinence.

Detrusor overactivity is the most common form of urine incontinence in older adults and is characterized by uninhibited bladder contractions causing an uncontrollable urge to void.

As a result of detrusor overactivity urinary frequency, urge incontinence and nocturnal incontinence occur.

Treatment of bladder overactivity is bladder retraining, pelvic floor therapy or the use of drugs that inhibit bladder contractions such as oxybutinin and tolterodine.

Acts on M2 and M3 subtypes of muscarinic receptors.

Has fewer side effects than oxybutynin and targets the bladder more than other areas of the body.

Side effects:Xerostomia, decreased gastric motility, headache, constipation, dry eyes and sleepiness.

The following reactions have been reported in patients who have taken tolterodine since it has become available:

Should not be used in patients with myasthenia gravis and angle closure glaucoma.

Leave a Reply

Your email address will not be published. Required fields are marked *